Results 181 to 190 of about 52,424 (257)

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort   +8 more
wiley   +1 more source

Biomaterials for modulating cellular responses of endogenous tendon stem/progenitor cells: A promising avenue for tendon regeneration

open access: yesBMEMat, EarlyView.
This review comprehensively summarizes emerging biomaterial‐based strategies and underlying mechanisms for modulating endogenous tendon stem/progenitor cells (TSPCs). It offers the most recent insights into TSPC physiology and potential applications of tissue engineering and regenerative medicine in tendons.
Zeyu Zhu   +9 more
wiley   +1 more source

Metal nanostructure‐coupled label‐free localized surface plasmon resonance biosensors for rapid and sensitive disease diagnosis

open access: yesBMEMat, EarlyView.
LSPR biosensing enables rapid, sensitive, and low‐sample‐volume detection of biomarkers, with broad applications in diagnosing cancer, infectious, and chronic diseases. Advances in nanostructure design, micro/nanofabrication, and microfluidic integration have expanded the potential of LSPR sensors in biomedical diagnostics.
Zhaoxin Geng   +4 more
wiley   +1 more source

Sequential catalytic nanosystem of carbon dots and uricase integrated with polydopamine for therapy of gouty wound ulceration

open access: yesBMEMat, EarlyView.
Sequential dual‐catalytic treatment of the gout wound ulceration process by CDs‐Uri@PDA. (a) Synthesis steps and morphology of CDs‐Uri@PDA. (b) Sequential treatment process and mechanism of CDs‐Uri@PDA for gout wound ulceration according to (i) uric acid reduction, (ii) antibacterial activity, and (iii) anti‐inflammatory effects.
Yonglan Yang   +11 more
wiley   +1 more source

A narrow bandgap Schottky heterojunction Fe2N/CeO2 microneedle triggering sonodynamic reactive oxygen species storm for drug‐resistance‐free skin fungal infection

open access: yesBMEMat, EarlyView.
Inorganic sonosensitizers suffer from inefficient electron‐hole separation, rapid recombination, and wide bandgaps in anti‐fungal applications. We propose MN@Fe2N/CeO2 to directly eliminate fungi without drug resistance. Combining semiconductor CeO2's advantages with Fe2N's high work function and activity enables efficient Schottky heterojunctions ...
Li Wang   +13 more
wiley   +1 more source

Nanomedicine‐driven innovations in postoperative cancer immunotherapy: Remodeling tumor microenvironment and precision delivery strategies

open access: yesBMEMat, EarlyView.
Nanomedicine‐Driven Strategies for Suppressing Postoperative Tumor Recurrence. This schematic illustrates three pivotal nanomedical strategies that synergistically counteract recurrence by targeting residual disease and the immunosuppressive tumor microenvironment within the surgical cavity.
Lisong Pang   +8 more
wiley   +1 more source

Exosome‐mimetic vesicle‐encapsulated multi‐responsive antibacterial hydrogel core‐shell microneedle patch promotes scarless healing of infected wounds

open access: yesBMEMat, EarlyView.
The core‐shell microneedle patch VP@FNV‐CuO2‐MN was fabricated by encapsulating n‐CuO2 in a moderately crosslinked PVA/CMCS/Borax4 hydrogel shell and VP‐loaded fibroblast membrane nanovesicles (VP@FNV) in a highly crosslinked PVA/CMCS/Borax6 hydrogel core. Upon application to an infected wound, the acidic microenvironment triggers Fenton‐like reactions
Ziwei Jiang   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy